J90.F NUREXONE BIOLOGIC INC.

Healthcare Biotechnology Frankfurt Exchange
0.2810 EUR
Close of Nov 12, 2026
0.2420 0.4700
Market cap
EUR 25.9M
P/E
-
P/B
24.15x
ROE
-544.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is J90.F undervalued?

Graham number

The Graham number of NUREXONE BIOLOGIC INC. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NUREXONE BIOLOGIC INC. fundamental analysis

No fundamental analysis for NUREXONE BIOLOGIC INC. yet.

NUREXONE BIOLOGIC INC. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NUREXONE BIOLOGIC INC.

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.

Full company profile